It's a great victory for the French unicorn.
A few days ago, Owkin obtained the green light from Brussels to market two tools based on artificial intelligence (AI) which aim to transform the management of breast and colorectal cancers.
They are already being tested in several French hospitals.
To discover
OUR FILE - Elizabeth II, a rock and a symbol for England
Based on the analysis of thousands of digital images of biopsies, Owkin's technology makes it possible to assess the risk of recurrence for patients with early breast cancer.
The oncologist can thus adapt the treatment according to the risk of each patient and avoid unnecessary and invasive chemotherapy for those at low risk.
Currently, these risks of relapse are identified by means of expensive and time-consuming molecular or genetic tests.
“
Our mission is to use AI to find the best treatment for each patient ,
”
summarizes Meriem Sefta, Head of Diagnostics at Owkin.
Read alsoAI in drugs: Owkin will receive at least $80 million from BMS
From diagnosis to research through…
This article is for subscribers only.
You have 83% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login